Therapeutic advances in cutaneous T-cell lymphoma (CTCL): From retinoids to rexinoids

Seminars in Oncology

Volumn 33, Issue SUPPL. 3, 2006, Pages 7-10

  Stadler, Rudolf ^a   Kremer, Almut ^a  

^a KLINIKUM MINDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BEXAROTENE; ETRETINATE; ISOTRETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; RETINOL; VITAMIN D RECEPTOR;

ACNE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO DEVELOPMENT; GENODERMATOSIS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERKERATOSIS; ONCOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; TERATOGENICITY;

EID: 33644513696     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.016     Document Type: Article

References (16)

1. L.T. Farol, K.B. Hymes Bexarotene A clinical review Expert Rev Anticancer Ther 4 2004 180 188
2. C. Zhang, P. Hazarika, X. Ni Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells Relevance to mechanism of therapeutic action Clin Cancer Res 8 2002 1234 1240
3. P. Chambon The retinoid signaling pathway molecular and genetic analyses Semin Cell Biol 5 1994 115 125
4. L. Tracey, R. Villuendas, A.M. Dotor Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway An expression profile study Blood 102 2003 1042 1050
5. D. Breneman, M. Duvic, T. Kuzel Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma Arch Dermatol 138 2002 325 332
6. P. Heald, M. Mehlmauer, A.G. Martin Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma Results of the phase III clinical trial J Am Acad Dermatol 49 2003 801 815
7. G. Mahrle, B. Thiele Retinoids in cutaneous T cell lymphomas Dermatologica 175 1987 145 150 (suppl 1)
8. V.A. Miller, F.M. Benedetti, J.R. Rigas Initial clinical trial of a selective retinoid X receptor ligand, LGD1069 J Clin Oncol 15 1997 790 795
9. N.A. Rizvi, J.L. Marshall, W. Dahut A Phase I study of LGD1069 in adults with advanced cancer Clin Cancer Res 5 1999 1658 1664
10. M. Duvic, A.G. Martin, Y. Kim Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma Arch Dermatol 137 2001 581 593
11. M. Duvic, K. Hymes, P. Heald Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma multinational phase II-III trial results J Clin Oncol 19 2001 2456 2471
12. C. Querfeld, S.T. Rosen, J. Guitart Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma J Am Acad Dermatol 51 2004 25 32
13. K.S. McGinnis, J.M. Junkins-Hopkins, G. Crawford Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma Clinical synergism and possible immunologic mechanisms J Am Acad Dermatol 50 2004 375 379
14. S. Michaelis, A. Cozzio, W. Kempf Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides Dermatology 209 2004 72 74
15. F. Singh, M.G. Lebwohl Cutaneous T-cell lymphoma treatment using bexarotene and PUVA A case series J Am Acad Dermatol 51 2004 570 573
16. R. Stadler, H.G. Otte, T. Luger Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II Blood 92 1998 3578 3581